Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510100 | 0.77 | SMN1; SMN2 (0.39) | KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL3640530 | 0.74 | KMT2A (0.65) | KMT2ANPSR1SMN1; SMN2HTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL6991460 | 0.73 | KMT2A (0.62) | KMT2ANPSR1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL4167074 | 0.72 | MEN1 (0.52) | KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL11321780 | 0.72 | KMT2A (0.32) | KMT2ANPSR1SMN1; SMN2HTT | |
| SCHEMBL15211213 | 0.72 | CCR1 (0.39) | KMT2ANPSR1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL3403920 | 0.71 | KMT2A (0.33) | KMT2ANPSR1ALDH1A1 | |
| SCHEMBL1336683 | 0.71 | PGK1 (0.42) | KMT2ANPSR1ALDH1A1 | |
| SCHEMBL403867 | 0.70 | KMT2A (0.39) | KMT2ANPSR1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL18998281 | 0.70 | KMT2A (0.35) | KMT2ANPSR1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1444228-B1 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | INST FOR PHARM DISCOVERY INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | GPR119, LIPA, LIPC | KMT2A 3555/4885NPSR1 1579/4885SMN1; SMN2 4596/4885 |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | GPR119, LIPA, DDC | KMT2A 3431/4885NPSR1 1161/4885SMN1; SMN2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.